In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bard licenses AAA endoluminal graft device from Endologix

Executive Summary

CR Bard has licensed exclusive European and Australian distribution rights to endovascular abdominal aortic aneurysms (AAAs) surgical device start-up, Endologix's minimally invasive endoluminal graft (ELG) for treating AAAs or weakening of the aortic wall. As part of the agreement, Bard has optioned the right to acquire all Endologix outstanding shares at an undisclosed pre-set price by the end of 2000.
Deal Industry
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Marketing (Licensing)

Related Companies